预约演示

First Wave signs up Rho for phase 2 trial of gastrointestinal drug

2022-11-03

First Wave Biopharma has signed CRO Rho to run a phase 2 trial for the biopharma’s treatment for exocrine pancreatic insufficiency that is expected to launch by the end of the year.

First Wave Biopharma has inked a deal for Rho to run a phase 2 trial of the biopharma’s treatmentexocrine pancreatic insufficiencyiency (EPI) associated with cystic fibrosis and chronic pancreatitis.

First Wave Biopharmaase is an oral recombiRhot lipase enzyme that is designed to break up fat moleculeexocrine pancreatic insufficiency (EPI)s so the moleculecystic fibrosised aschronic pancreatitisg to the Cystic Fibrosis Foundation, more than 30,000 people in the U.S. suffer from EPI caused by cystic fibrosis, and the National Pancreas Foundation estimates about 90,000 patients in the country have EPI caused by chronic pancreatitis.

First Wavenagadrulipaselinical programs involving adrulipase. The latest trial is expected to begin by the end of the year, First Wave said in an Oct. 31 press release. Financial terms weren’t disclosed.Cystic Fibrosis Foundation Cystic Fibrosis EPI cystic fibrosis EPI chronic pancreatitis

Rhosearch, including data recently presented at AAadrulipasendicates the new adrulipase formulation should deliver the drug in the intended area of the gastrointestinal tract,” First Wave CEO James Sapirstein said in the release.